Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACER-801 for Vasomotor Symptoms in Menopause
NCT05325775Phase 2Completed
- Sponsor
- Acer Therapeutics Inc.
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osanetant in vasomotor symptoms, sponsored by Acer Therapeutics Inc.. Started Mar 2022; status: completed.
02
Drugs
osanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05325775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325775.